Mayinglong Pharmaceutical Holds Steady as Market Benchmarks Shift
The Shanghai Stock Exchange saw Mayinglong Pharmaceutical (600993.SS) trade flat during the 24‑hour period ending at 11:07 PM Central Europe on Thursday, 22 October 2026. At the close, the stock stood at CNY 23.61, unchanged from the opening price. This static performance comes amid a broader market that has largely been neutral, with several peers also recording zero percentage change over the same interval.
Current Positioning
- Shares Outstanding: 444.2 million
- Market Capitalisation: CNY 10.5 billion
- Volume Traded in Last 24 Hours: Approximately CNY 223.5 million
These figures place Mayinglong at a mid‑tier valuation compared to its peers. The company’s 200‑day simple moving average sits at CNY 23.32, indicating a recent trend that has been relatively flat. The most recent 52‑week high of CNY 30.18, achieved on 19 December 2025, remains roughly 27 % above the current level, while the 52‑week low of CNY 21.22 (recorded on 1 July 2026) is only about 10 % below today’s price.
Recent Performance
Since the end of last month, Mayinglong Pharmaceutical has experienced a modest 5.23 % increase in share price. This uptick reflects incremental gains from investor confidence in the company’s product pipeline and steady revenue streams from its core pharmaceutical offerings.
Peer Comparisons
| Stock | 24‑Hour Movement | Current Price (CNY) | Market Cap (CNY bn) | P/E Ratio |
|---|---|---|---|---|
| Lizhong Sitong Light Alloy (300428.SZ) | 0 % | 17.98 | 12.6 | 11.37 |
| Ireader (603533.SS) | 0 % | 26.77 | 12.6 | — |
| Jinko Power (601778.SS) | 0 % | 3.74 | 12.6 | 679.97 |
| Lianhe Chemical (002250.SZ) | 0 % | 13.24 | 12.6 | 24.62 |
| Sichuan Swellfun (600779.SS) | 0 % | 25.02 | 12.6 | 42.74 |
The table highlights that Mayinglong’s valuation sits comfortably between the low‑priced Jinko Power and the higher‑priced Ireader. Its P/E ratio is not disclosed in the current data, but its market cap and trading activity suggest a stable position within the Chinese pharmaceutical sector.
Strategic Context
Mayinglong Pharmaceutical Group Co., Ltd. is headquartered in Wuhan and specializes in a broad spectrum of pharmaceutical products, including hemorrhoid plasters, traditional Chinese medicines, oral tablets, and related medical equipment and health foods. Having been listed on the Shanghai Stock Exchange since its IPO on 23 April 2004, the company has maintained a consistent presence in the market, supported by a diversified product line and a robust distribution network.
Outlook
With the 200‑day moving average close to today’s price and a steady 52‑week trading range, investors may view Mayinglong as a reliable, if unremarkable, holding in a portfolio. The company’s ongoing product development, coupled with its established market reach, provides a foundation for potential incremental upside, particularly if it can leverage its traditional medicine expertise to capture growing domestic demand. Market observers will likely watch for any new product launches or regulatory approvals that could tilt the balance toward a more pronounced price movement in the coming weeks.
